News and Updates

iVeena awarded top prize for most promising new products in the field of ophthalmology at the American Society of Cataract and Refractive Surgeons annual conference.

20 May 2019

iVeena receives top award at the American Society of Cataract and Refractive Surgeons

At the May 4, 2019 American Society of Cataract and Refractive Surgeons, Dr. Ambati (iVeena President and Founder) presented the iVeena products in development at the inaugural Winning Pitch Challenge. The Challenge was chaired by prominent Key Opinion leaders and institutional investors. The esteemed panel of KOL's and industry leading judges voted iVeena's keratoeonus and progressive myopia projects the best out of 60 submissions and awarded Dr. Ambati the top prize.  "In short, the Academy award suggests that these two iVeena projects are two of the most promising technologies in the field of ophthalmology today said Jerry Simmons, CEO of iVeena Delivery Systems.”

iVeena announces the commencement of a 36 patient Phase 1/2a pilot clinical study for the treatment of keratoconus.

04 February 2019

iVeena announces the commencement of a 36 patient Phase I/2a pilot clinical study for the treatment of Keratoconus (IVMED-80). The Company has Orphan Drug Designation for this product.

Mountain Pacific Venture Fund invests in ocular drug development company iVeena

04 February 2019

iVeena announces the first close for its $2.75M Series B financing by Mountain Pacific Venture Fund, a health care/biotech focused venture fund.

iVeena receives Notice of Allowance from the US Patent Office for patent protecting cataract implants (IVMED 10&20).

12 December 2017

Salt Lake City, Utah,--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a biopharmaceutical company that develops innovative ophthalmology products, today announced that the United States Patent and Trademark Office (USPTO) communicated a notice of allowance for a patent assigned to the University of Utah and licensed to iVeena Delivery Systems Inc.

iVeena Receives FDA Orphan Drug Designation for IVMED-80 for the Treatment of Keratoconus

30 October 2017

iVeena announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IVMED-80, for the treatment of keratoconus. Keratoconus is a degenerative disorder causing a cornea to become conical in shape that can seriously distort vision. This may lead to a corneal transplant. IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea.

iVeena Completes Phase I/2a Pilot Clinical Study of IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant to Treat Inflammation and Pain Associated with Cataract Surgery

28 October 2017

iVeena Completes Phase 1/2a Pilot Clinical Study for IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant that Delivers Dexamethasone to Both Anterior and Posterior Eye Segments to Treat Inflammation and Pain Associated with Cataract Surgery.

iVeena has been awarded a total of $450K in NSF and NIH grants to advance its Keratoconus Orphan Drug candidate and Gene Therapy programs.

06 September 2017

"iVeena is pleased to receive a total of $450K in Federal Government grants to advance its portfolio programs," said Gerald Simmons, CEO. "$225K is an NIH grant for its Keratoconus Orphan Drug candidate. IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea. $225K is an NSF grant for iVeena’s Gene Therapy program for various ophthalmic applications.”

iVeena announces the initiation of its Phase I/2b in-human pilot clinical study for IVMED-10, a bioerodable implant designed to eliminate the need for eye drops after cataract surgery.

31 May 2017

On Monday, May 30th, iVeena initiated the Phase I/2a pilot clinical study for IVMED-10. This product is a bioerodable dexamethasone implant given at the time of cataract surgery that releases the drug in the lens capsule over an approximate two week period. “This product is designed to eliminate the need for daily administration of a steroid and an NSAID that published reports show is highly confusing and difficult for a significant portion of the older target population that under go cataract surgery," said Jerry Simmons, CEO. The market for post surgery cataract drops exceeds $1B annually. Results of the study should be available late July or early August, this year.